1. Home
  2. MINE vs BDSX Comparison

MINE vs BDSX Comparison

Compare MINE & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mayfair Gold Corp. Common Shares

MINE

Mayfair Gold Corp. Common Shares

N/A

Current Price

$2.32

Market Cap

170.5M

Sector

Energy

ML Signal

N/A

Logo Biodesix Inc.

BDSX

Biodesix Inc.

HOLD

Current Price

$21.94

Market Cap

153.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MINE
BDSX
Founded
2019
2005
Country
Canada
United States
Employees
9
N/A
Industry
Oil & Gas Production
Precision Instruments
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
170.5M
153.3M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
MINE
BDSX
Price
$2.32
$21.94
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$32.50
AVG Volume (30 Days)
26.4K
94.5K
Earning Date
05-06-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$88,499,000.00
Revenue This Year
N/A
$25.26
Revenue Next Year
N/A
$19.15
P/E Ratio
N/A
N/A
Revenue Growth
N/A
24.08
52 Week Low
$2.16
$0.29
52 Week High
$4.45
$24.92

Technical Indicators

Market Signals
Indicator
MINE
BDSX
Relative Strength Index (RSI) 42.37 57.26
Support Level $2.16 $6.63
Resistance Level $2.87 $24.92
Average True Range (ATR) 0.18 2.38
MACD 0.01 -0.14
Stochastic Oscillator 27.34 55.04

Price Performance

Historical Comparison
MINE
BDSX

About MINE Mayfair Gold Corp. Common Shares

Mayfair Gold Corp is a mineral exploration company that is engaged in the acquisition and exploration of mineral properties. It has one material mineral property, the Fenn-Gib Gold Property, located in the Guibord, Munro, Michaud, and McCool Townships in northeast Ontario, which is in the exploration stage.

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.

Share on Social Networks: